Healthcare Industry News: Eli Lilly
News Release - October 8, 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive OfficerSEATTLE--(HSMN NewsFeed)--Calistoga Pharmaceuticals, Inc., a company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, today announced the appointment of Carol G. Gallagher, Pharm. D., as Chief Executive Officer. With previous leadership roles at both large and small biopharmaceutical companies, Dr. Gallagher brings expertise in business and drug development. During her tenure at Biogen Idec, Dr. Gallagher led the Rituxan team when oncology sales first surpassed $1 billion and the rheumatoid arthritis and multiple sclerosis development programs were designed.
“We are very excited to have an executive with Carol’s broad industry experience, skills and achievements join Calistoga as the Company’s first chief executive officer, and we know her leadership will serve our company well,” said W. Michael Gallatin, Ph.D., President of Calistoga. “Carol has been instrumental in strategic planning and corporate development across multiple therapeutic areas and has demonstrated her ability to foster alliances with leading firms. With our first compounds entering clinical trials and our business development activities underway, Carol’s experience and leadership will complement our experienced scientific and operational team.”
“Carol’s extensive accomplishments include successful business transactions at Anadys and CancerVax and product development expertise at Biogen Idec, where she helped grow and expand the Rituxan program in oncology and autoimmune disease,” said James Topper, M.D., Ph.D., Chairman of the Board of Directors. “She is an excellent addition to the Calistoga management team.”
Dr. Gallagher, 44, joins Calistoga Pharmaceuticals after recently serving as President and CEO of Metastatix, a private oncology company. Prior to that, she held senior leadership roles at Anadys Pharmaceuticals as Senior Vice President of Corporate Development and CancerVax as Vice President of Product Planning. At CancerVax, where she worked from 2003 to 2006, she was part of the management team that executed the Canvaxin license with Serono and the subsequent reverse merger with Micromet, Inc. Beginning in 2002, Dr. Gallagher led the Rituxan collaboration and oncology marketing at Biogen Idec. Dr. Gallagher also led oncology and ophthalmology global marketing planning at Pfizer, joining Pfizer through the acquisition of Warner Lambert and Agouron Pharmaceuticals.
Dr. Gallagher began her career in sales and marketing at Eli Lilly and also held various sales and marketing roles at Amgen prior to joining Agouron Pharmaceuticals in 1997. She received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.
“Calistoga’s differentiated PI3K program and high caliber executive team offer a very exciting opportunity,” said Gallagher. “The Company has made extensive progress since its founding to advance its first product candidate into clinical development in oncology and, in the near future, inflammatory disease. I look forward to building upon this promising foundation.”
About Calistoga Pharmaceuticals
Calistoga Pharmaceuticals is developing multiple compounds which selectively target the PI3 kinase pathway. The PI3 kinase family regulates immune cell activation and stimulates cell proliferation, growth, motility, metabolism and survival and is often upregulated in cancer and inflammatory diseases. The Company’s lead compound, CAL-101, is under clinical evaluation in patients with hematologic malignancies in a Phase 1 trial. A clinical trial evaluating CAL-101 in an inflammatory disease setting is planned for early 2008. Calistoga is a privately held organization headquartered in Seattle, Washington. For more information, visit the Company’s website at: www.calistogapharma.com.
Source: Calistoga Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.